Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qixue Bingzhi (also referred to as Qi-Xue-Bing-Zhi) is a multi-component Traditional Chinese Medicine (TCM) herbal formulation investigated for its potential therapeutic effects in cardiovascular diseases. The recipe is primarily studied for its ability to inhibit the proliferation of vascular smooth muscle cells (VSMCs), a critical factor in the pathogenesis of atherosclerosis and vascular restenosis. Research has identified several key active components within its effective fractions, including paeoniflorin, naringin, and neohesperidin. The pharmacological mechanism is thought to involve the downregulation of platelet-derived growth factor (PDGF) and its corresponding receptor (PDGFR) gene expression, thereby modulating cellular signaling pathways associated with vascular remodeling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qixue Bingzhi.